本报讯 （记者李勇）恒力石化股份有限公司（以下简称"恒力石化"）2月27日晚间披露的公告显示，该公司实际控制人之 一陈建华于近期通过集中竞价交易方式累计增持该公司股份2019.86万股，占该公司总股本的0.29%，累计增持金额为5亿元。 光大证券在发布的相关研报中点评称，自2025年7月中下旬以来，随着大炼化行业景气度逐步修复，恒力石化股价涨幅显 著，当前时点实控人增持股份，展现出对该公司未来发展的信心。 （编辑 郭之宸） 2025年4月8日，恒力石化发布公告称于当日接到实际控制人之一陈建华通知，其计划自2025年4月9日起的12个月内以自有 资金或自筹资金增持该公司股份不低于5亿元，不超过10亿元。2026年2月3日，陈建华进行了此轮增持的首次增持。截至2月27 日，此轮增持已累计增持5亿元，达到增持计划下限要求，本次增持计划已实施完毕。 ...

Group 1 - The core viewpoint of the news is that Capbio (凯普生物) experienced a significant stock price increase, reaching a limit up of 20.03% on January 26, 2026, with a total market capitalization of 4.687 billion yuan [1] - Capbio has recently announced the acquisition of multiple domestic and international patent authorizations, enhancing its technological barriers and core competitiveness [2] - The actual controller, Ms. Wang Jianyu, has completed an increase in holdings amounting to 18.12 million yuan and plans to continue increasing her stake, signaling confidence in the company's development [2] - The company has expanded its business scope by obtaining production qualifications for Class III in vitro diagnostic reagents and Class II obstetric and gynecological instruments [2] - For the first three quarters of 2025, Capbio reported a narrowing of net losses attributable to shareholders by 51.25%, with operating cash flow increasing by 173.06% to 121 million yuan, indicating an improvement in operational conditions [2] - Capbio, as an integrated supplier of molecular diagnostic products and services, is expected to benefit from the growth in the in vitro diagnostics sector within the biopharmaceutical industry [2] - On the market performance side, the biopharmaceutical sector saw active movements, with Capbio's limit-up creating a certain sector linkage effect [2] - Technical indicators such as the MACD forming a golden cross and breaking through the upper Bollinger Band may attract more capital attention [2] - There was likely a flow of main funds into the stock, contributing to the price surge [2]

Core Viewpoint - The resignation of Dai Sijue as the chairman of Baolingbao (002286.SZ) due to personal reasons marks a significant change in the company's leadership, with implications for its governance and future direction [1][2]. Group 1: Leadership Changes - Dai Sijue submitted his resignation as chairman, director, and head of the board's strategic committee, effective November 17, 2025, but will continue to serve on the boards of two subsidiaries [1]. - Dai Sijue, born in January 1995, became the youngest chairman in A-share history at age 26 in March 2021 and has been the actual controller of Baolingbao since 2017 [2][3]. Group 2: Company Performance - Baolingbao reported a net profit attributable to shareholders of 111 million yuan for 2024, a year-on-year increase of 105.97%, with a non-recurring profit growth of 254.56% [3]. - For the first three quarters of 2025, the company achieved a revenue of 2.126 billion yuan, up 15.98% year-on-year, and a net profit of 134 million yuan, reflecting a 32.58% increase [3]. Group 3: Shareholding and Control Issues - The actual control of Baolingbao shifted from Dai Sijue alone to a joint control with his brother, Dai Sicong, following an agreement signed on August 19, 2024 [4]. - A shareholding increase plan was announced by the new controlling party, aiming to acquire between 5% and 10% of the company's shares, but progress has been significantly delayed, with only 129,940 shares acquired by October 10, 2025 [6]. - The controlling shareholder, Yongyu Investment, is facing financial pressures, having been listed as an executed party in multiple court cases with significant amounts involved, including 35.16 million yuan and 66.20 million yuan [7].